Document is current
Any future updates will be listed below
-
Authors
Goyal, Gaurav https://orcid.org/0000-0001-6148-5177
Acosta-Medina, Aldo A. https://orcid.org/0000-0001-9414-9153
Go, Ronald S. https://orcid.org/0000-0002-8284-3495
Abeykoon, Jithma P. https://orcid.org/0000-0003-3939-6252
,
Zanwar, Saurabh
Ruan, Gordon
Rech, Karen L.
Ravindran, Aishwarya
Bennani, N. Nora
Davidge-Pitts, Caroline J.
Koster, Matthew J.
Ryu, Jay
Shah, Mithun V.
Tobin, W. Oliver
Vassallo, Robert
Young, Jason R.
Goyal, Gaurav
- License Information
-
More Information
Article History
Received: 3 June 2025
Revised: 5 June 2025
Accepted: 7 July 2025
First Online: 15 July 2025
Competing interests
: GG has served on advisory boards of Sobi, Electra, and Seagen and receives consulting fees from Recordati and PharmaEssentia (outside of the submitted work); MJK has served in the advisory board of Amgen and has received writing services fees from Genentech; MVS has received research funding to the institution from AbbVie, Celgene, KURA Oncology, and MRKR Therapeutics; NNB has served in the advisory boards of Secure Bio, Affimed GmbH, Astellas Pharma, and Acrotech Biopharma LLC, in the Scientific Advisory committee of Acrotech Biopharma LLC, and in tumor board educational activities with OncoLens with no personal compensation for any of the advisory boards; RV has received funding from Pfizer, Bristol Myers Squibb and Sun Pharma, and has received consultancy fees from Sanofi.
: This Letter serves as a Reply to the Correspondence published by Pergoraro et al. [] pertaining to our group’s recent publication in Leukemia []. The referenced study complies with all relevant ethical guidelines and regulations according to the Declaration of Helsinki and was approved by the pertinent Institutional Review Boards.
